Cargando…
How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?
High mortality and morbidity rates associated with severe infections in the critically ill continue to be a significant issue for the healthcare system. In view of the diverse and unique pharmacokinetic profile of drugs in this patient population, there is increasing use of therapeutic drug monitori...
Autores principales: | Wong, Gloria, Sime, Fekade Bruck, Lipman, Jeffrey, Roberts, Jason A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289211/ https://www.ncbi.nlm.nih.gov/pubmed/25430961 http://dx.doi.org/10.1186/1471-2334-14-288 |
Ejemplares similares
-
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review
por: Sime, Fekade Bruck, et al.
Publicado: (2012) -
Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
por: Sime, Fekade B., et al.
Publicado: (2018) -
We need to optimize piperacillin-tazobactam dosing in critically ill patients—but how?
por: Cotta, Menino Osbert, et al.
Publicado: (2016) -
Population Pharmacokinetics of Unbound Ceftolozane and Tazobactam in Critically Ill Patients without Renal Dysfunction
por: Sime, Fekade B., et al.
Publicado: (2019) -
Cerebrospinal Fluid Penetration of Ceftolozane-Tazobactam in Critically Ill Patients with an Indwelling External Ventricular Drain
por: Sime, Fekade B., et al.
Publicado: (2020)